Retrieved from Reddivari, A
(Please note: only one case report has been found against polyarthritis induced by glp-1 agonists.) Determining what type of joint pain Ozempic can cause is a complex process since it depends on various factors including individual health condition, the dosage and duration of the medication, and possibly other currently unknown factors
Tirzepatide, a dual GLP-1 and GIP receptor agonist, has been newly approved by the FDA for managing moderate to severe OSA, following promising results from major randomized trials
Moreover, despite more semaglutide-treated patients starting at doses higher than the minimal dose and reaching the higher approved maintenance doses (i.e., 10 mg for tirzepatide and 1.7 mg for semaglutide) during follow-up, weight reduction remained greater in the tirzepatide group
European journal of gastroenterology & hepatology